Search

Objective: To compare the perioperative outcomes of robotic single-site myomectomy (RSSM) and laparoendoscopic single-site myomectomy (LSSM).Methods: From January 2017 to December 2019, electronic medical records of the consecutively held 17 RSSM and 20 LSSM were reviewed. Parameters including patient’s characteristics, the total operation time, size and number of myomas taken out, operative findings, intra and postoperative complications were compared.Results: Patients who undertook RSSM were younger (27.0±7.1 vs. 32.9±7.9) and only one out of 17 (2.9%) had previous pregnancy compared to 10 out of 20 in LSSM (50.0%). Complex cases with tumors of larger size and accompanied adhesion were done using RSSM. The median operative time was longer in the RSSM (176.1±59.0 vs. 77.5±47.1). All cases were successfully performed via a single port. No cases of postoperative complication including wound dehiscence or intestinal obstruction occurred in either group.Conclusion: Perioperative outcomes of myomectomy undertaken by robotic single-site surgery and laparoendoscopic single-site surgery were comparable, though myomectomy for the larger myoma were performed with robotic single-site surgery. The role of robotic single-site myomectomy on fertility needs further investigation.

Background: Allergy health problems worldwide are mainly caused by allergens from domestic cats ( Felis catus). Fel d 1 is a major allergen that causes severe allergic reactions in humans, including rhinitis, conjunctivitis, and life-threatening asthma. The treatment for allergic reactions to Fel d 1 in humans is still in its infancy. Patients with cat allergies anticipate hypoallergenic cats. Methods: We used the CRISPR-Cas9 system, microinjection, and embryo transfer to knock out the chain 2 (CH2) genome of Fel d 1 in cats. T7 endonuclease 1 (T7E1) assay and Sanger sequencing analysis were used to confirm CH2 knockout cats. Fel d 1 level in CH2 knockout cats was assessed by enzyme-linked immunosorbent assay (ELISA). Cytoplasm injection clone technology (CICT) was used to clone the CH2 knockout cat. Results: We report the first successful generation and cloning of CH2 knockout cats using the CRISPR-Cas9 system and CICT. CH2 knockout cats were confirmed using T7E1 and Sanger sequencing. Cloned CH2 knockout cat was verified by microsatellite analysis. Remarkably, ELISA proved that Fel d 1 level of CH2 knockout cats was extremely low compared with that of wild type domestic cats. Conclusion: CH2 knockout cats we generated showed an extremely low level of Fel d 1 and could be hypoallergenic cats. Our study indicates that creating hypoallergenic cats using the CRISPR-Cas9 system is a significant step forward in the consequence that these cats can safely approach allergic patients.